Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Circulating Tumor DNA-Informed Adjuvant Therapy for Intermediate-Risk Head and Neck Cancer

NCT07932067 is a not-yet-recruiting phase 2 trial at UPMC Hillman (estimated enrollment 140), led by Kevin Contrera, of surgical drain-fluid ctDNA (LymphDetect Head and Neck) to inform adjuvant therapy in intermediate-risk, HPV-negative head and neck cancer, with 2-year locoregional control in SDF-positive intermediate-risk patients as the primary endpoint. The registry site is UPMC, not Cleveland Clinic.

ClinicalTrials.gov